These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26815881)

  • 1. Antithyroid Drug Side Effects in the Population and in Pregnancy.
    Andersen SL; Olsen J; Laurberg P
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1606-14. PubMed ID: 26815881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study.
    Andersen SL; Olsen J; Wu CS; Laurberg P
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4373-81. PubMed ID: 24151287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graves'-Basedow disease in pregnancy. New trends in the management and guidance to reduce the risk of birth defects caused by antithyroid drugs.
    Laurberg P; Andersen SL
    Nuklearmedizin; 2015; 54(3):106-11. PubMed ID: 26105719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Birth defects after use of antithyroid drugs in early pregnancy: a Swedish nationwide study.
    Andersen SL; Lönn S; Vestergaard P; Törring O
    Eur J Endocrinol; 2017 Oct; 177(4):369-378. PubMed ID: 28780518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severity of birth defects after propylthiouracil exposure in early pregnancy.
    Andersen SL; Olsen J; Wu CS; Laurberg P
    Thyroid; 2014 Oct; 24(10):1533-40. PubMed ID: 24963758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis.
    Agrawal M; Lewis S; Premawardhana L; Dayan CM; Taylor PN; Okosieme OE
    Clin Endocrinol (Oxf); 2022 Jun; 96(6):857-868. PubMed ID: 34845757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Congenital anomalies in children exposed to antithyroid drugs in-utero: a meta-analysis of cohort studies.
    Li H; Zheng J; Luo J; Zeng R; Feng N; Zhu N; Feng Q
    PLoS One; 2015; 10(5):e0126610. PubMed ID: 25974033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk?
    Laurberg P; Andersen SL
    Eur J Endocrinol; 2014 Jul; 171(1):R13-20. PubMed ID: 24662319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithyroid Drug Use in Pregnancy and Birth Defects: Why Some Studies Find Clear Associations, and Some Studies Report None.
    Laurberg P; Andersen SL
    Thyroid; 2015 Nov; 25(11):1185-90. PubMed ID: 26359310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithyroid drug use during pregnancy and the risk of birth defects in offspring: systematic review and meta-analysis of observational studies with methodological considerations.
    Morales DR; Fonkwen L; Nordeng HME
    Br J Clin Pharmacol; 2021 Oct; 87(10):3890-3900. PubMed ID: 33783857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system.
    Lo JC; Rivkees SA; Chandra M; Gonzalez JR; Korelitz JJ; Kuzniewicz MW
    Thyroid; 2015 Jun; 25(6):698-705. PubMed ID: 25747892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of antithyroid drugs in pregnancy: update and therapy implications.
    Francis T; Francis N; Lazarus JH; Okosieme OE
    Expert Opin Drug Saf; 2020 May; 19(5):565-576. PubMed ID: 32223355
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatotoxicity and cutaneous reactions after antithyroid drug administration.
    Otsuka F; Noh JY; Chino T; Shimizu T; Mukasa K; Ito K; Ito K; Taniyama M
    Clin Endocrinol (Oxf); 2012 Aug; 77(2):310-5. PubMed ID: 22332800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment.
    Kobayashi S; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Ohye H; Suzuki M; Yoshihara A; Iwaku K; Sugino K; Ito K
    Thyroid; 2014 May; 24(5):796-801. PubMed ID: 24341564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study.
    Seo GH; Kim TH; Chung JH
    Ann Intern Med; 2018 Mar; 168(6):405-413. PubMed ID: 29357398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The propylthiouracil dilemma.
    Glinoer D; Cooper DS
    Curr Opin Endocrinol Diabetes Obes; 2012 Oct; 19(5):402-7. PubMed ID: 22820213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of methimazole and propylthiouracil in pregnancy: a systematic review.
    Hackmon R; Blichowski M; Koren G
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1077-1086. PubMed ID: 23231846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.
    Takata K; Kubota S; Fukata S; Kudo T; Nishihara E; Ito M; Amino N; Miyauchi A
    Thyroid; 2009 Jun; 19(6):559-63. PubMed ID: 19445623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Disproportionality Analysis of the Adverse Effect Profiles of Methimazole and Propylthiouracil in Patients with Hyperthyroidism Using the Japanese Adverse Drug Event Report Database.
    Arai M; Tsuno T; Konishi H; Nishiyama K; Terauchi Y; Inoue R; Shirakawa J
    Thyroid; 2023 Jul; 33(7):804-816. PubMed ID: 37130038
    [No Abstract]   [Full Text] [Related]  

  • 20. SIDE EFFECTS OF PTU AND MMI IN THE TREATMENT OF HYPERTHYROIDISM: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    Yu W; Wu N; Li L; Wang J; OuYang H; Shen H
    Endocr Pract; 2020 Feb; 26(2):207-217. PubMed ID: 31652102
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.